A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

NCT07256782
clinicaltrials.gov
Phase
Phase 1/Phase 2
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Participants
444
clinicaltrials.gov
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
clinicaltrials.gov
Start date
2025-10-24
clinicaltrials.gov
Number of sites
1
clinicaltrials.gov

Summary
QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of QLC5508 in combination with other anti-cancer agents in patients with advanced solid tumor patients.
clinicaltrials.gov
Short title
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
clinicaltrials.gov
Official title
A Phase Ib/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of QLC5508 in Combination With Other Anti-tumor Agents in Patients With Advanced Solid Tumors
clinicaltrials.gov

Control arm
Open label
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Phase
Phase 1/Phase 2
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2028-05-01
clinicaltrials.gov
First posted
2025-12-01
clinicaltrials.gov
Registry last updated
2025-12-01
clinicaltrials.gov
Primary completion date
2026-10-01
clinicaltrials.gov
Start date
2025-10-24
clinicaltrials.gov

Participants
444
clinicaltrials.gov
Participant count basis
Estimated
clinicaltrials.gov
Planned participants
444
clinicaltrials.gov
Protocol amendments
0
clinicaltrials.gov
Number of sites
1
clinicaltrials.gov

Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT07256782
clinicaltrials.gov
ClinicalTrials.gov ID
NCT07256782
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Not randomised
Model
Parallel groups
Purpose
Treatment
Masking
No masking
Sources for study design
clinicaltrials.gov

  1. Maximum tolerated dose (MTD) for combination-treatments (Phase Ib)

    Timeframe: Up to day 21 (Q3W combination) or day 28 (Q2W combination) from the first dose

    To determine the MTD for further evaluation of QLC5508 with other anti-cancer agents in participants with advanced solid tumors

  2. Recommended Phase II Dose (RP2D) for combination-treatments (Phase Ib)

    Timeframe: Up to day 21 (Q3W combination) or day 28 (Q2W combination) from the first dose

    To determine the RP2D for further evaluation of QLC5508 with other anti-tumor agents in participants with advanced solid tumors

  3. Objective response rate (ORR) determined by investigators (Phase II)

    Timeframe: Approximately 12 months

    ORR is defined as proportion of participants with best overall response of complete response (CR) and partial response (PR) \[Confirmed CR/PR assessment require at least one repeat (4-6 weeks)\] evaluated by investigator according to RECIST v1.1

  1. ORR determined by investigators (Phase Ib)

    Timeframe: Approximately 12 months

    ORR is defined as proportion of participants with best overall response of CR and PR \[Confirmed CR/PR assessment require at least one repeat (4-6 weeks)\] evaluated by investigator according to RECIST v1.1

  2. Disease control rate (DCR) determined by investigators (Phase Ib and II)

    Timeframe: Approximately 12 months

    DCR is defined as proportion of participants with best overall response of CR, PR and stable disease (SD) evaluated by investigator according to RECIST v1.1 \[Confirmed CR/PR assessment require at least one repeat (4-6 weeks)\]

  3. Duration of response (DOR) determined by investigators (Phase Ib and II)

    Timeframe: Approximately 12 months

    DOR is defined as the period from the first occurrence of CR or PR to PD or death from any cause \[Confirmed CR/PR assessment require at least one repeat (4-6 weeks)\]

  4. Progression-free survival (PFS) determined by investigators (Phase Ib and II)

    Timeframe: Approximately 12 months

    PFS is defined as the time from the first dose to PD or death from any cause.

  5. Overall survival (OS) (Phase Ib and II)

    Timeframe: Approximately 24 months

    OS is defined as the time from the first dose to death from any cause

  6. Incidence and severity of adverse events (AEs) (Phase II)

    Timeframe: From the first dose through 90 days post end of treatment

    Any untoward medical occurrence in a clinical study participant, which may manifest as symptoms, signs, diseases, or laboratory abnormalities, are assessed by investigator according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), v5.0

  7. Observed maximum plasma concentration (Cmax) of QLC5508 in advanced solid tumor (Phase Ib and II)

    Timeframe: From pre-dose to study completion, approximately 24 months

    Cmax will be obtained after administration of the first dose of QLC5508

  8. Time to reach maximum plasma concentration (Tmax) of QLC5508 (Phase Ib)

    Timeframe: From pre-dose to study completion, approximately 24 months

    Tmax will be obtained after administration of the first dose of QLC5508

  9. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of QLC5508 (Phase Ib)

    Timeframe: From pre-dose to study completion, approximately 24 months]

    Area under the plasma concentration versus time curve from time zero to the last sampling time when the concentration was no less than the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

  10. Observed maximum plasma concentration (Cmax) of QL1706 in advanced solid tumor (Phase Ib and II)

    Timeframe: From pre-dose to study completion, approximately 24 months

    Cmax will be obtained after administration of the first dose of QL1706

  11. Observed maximum plasma concentration (Cmax) of QL2107 in advanced solid tumor (Phase Ib and II)

    Timeframe: From pre-dose to study completion, approximately 24 months

    Cmax will be obtained after administration of the first dose of QL2107

  12. Percentage of participants with antibodies to QLC5508 in serum (Phase Ib and II)

    Timeframe: From pre-dose to study completion, approximately 24 months

    Serum samples were collected for the determination of anti-drug antibody (ADA) at designated time points.

  13. Percentage of participants with antibodies to QL1706 in serum (Phase Ib and II)

    Timeframe: From pre-dose to study completion, approximately 24 months

    Serum samples were collected for the determination of ADA at designated time points

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults, Older adults
Minimum age
18 Years
Healthy volunteers
No

  • At least 18 years of age at screening;
  • Histologically or cytologically confirmed advanced solid tumors:

Dose escalation part will enroll participants who have progressed on or are intolerant to available standard therapies.

Dose expansion part will enroll participants who have not received prior treatment for advanced/metastatic diseases.

  • At least one measurable target lesion according to RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1
  • Life expectancy ≥12 weeks
  • Female or male participants should be willing to use appropriate contraceptive measures throughout the study;
  • Female participants should have a negative blood pregnancy test within 7 days prior to the first dose or have evidence of non-childbearing potential;
  • A signed written Informed Consent Form

  • . Received or undergoing any of the following treatment:

    1. Previous or current treatment with B7-H3 targeted therapy
    2. Previous or current treatment with topoisomerase I inhibitors
    3. Previous treatment with cytotoxic chemotherapy, investigational agents, traditional Chinese medicine with an anti-tumor indication and antitumor drugs within 14 days prior to the first dose
    4. Previous treatment with macromolecular antitumor drugs within 28 days prior to the first dose

    f. Radiotherapy with a limited field of radiation within 2 weeks prior to the first dose; or more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first dose e. Pleural effusion or ascites requiring clinical intervention; or presence of pericardial effusion f. Major surgery within 4 weeks prior to the first dose g. Brain metastases; leptomeningeal or brainstem metastases; or spinal cord compression

  • Unresolved AEs ≥ Grade 2 (CTCAE v5.0) from prior therapy except for alopecia and residual neuropathy

  • Previous or concurrent primary malignancies

  • Inadequate bone marrow reserve or organ dysfunction

  • Evidence of cardiovascular risk

  • Evidence of current severe or uncontrolled systemic diseases

  • Severe infection within 4 weeks prior to the first dose; or uncontrolled active infection at screening

  • Known or suspected interstitial lung disease; or other moderate to severe pulmonary diseases that significantly impair respiratory function and may interfere with the detection or management of drug-related pulmonary toxicity

  • High risk of gastrointestinal or abdominal bleeding 10. Gastrointestinal diseases of clinical significance within 3 months prior to the first dose

  • History of severe neuropathy or mental disorders

  • History of severe hypersensitivity reaction, severe infusion reaction or idiosyncrasy to drugs chemically related to QLC5508 or any of the components of QLC5508

  • Unlikely to comply with study procedures and requirements in the opinion of the investigator

  • Any disease or condition that, in the opinion of the investigator, would compromise participant safety or interfere with study assessments

Sources for eligibility
clinicaltrials.gov

  • Shanghai East HospitalShanghai, ChinaRecruiting
Sources for sites
clinicaltrials.gov

Related records

Drugs (5)

Lead sponsors (1)

Targets (16)